Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Prostate cancer
Stage/Subtype:  stage II prostate cancer
Country:  U.S.A.
Trial Type:  Treatment
Trial Status:  Active
Results 1-25 of 118 for your search:
Start Over
Stereotactic Body Radiotherapy for Prostate Cancer
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 11-022, NCT01352598
Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
Phase: Phase IV
Type: Treatment
Status: Active
Age: 40 and over
Sponsor: Other
Protocol IDs: Thin-1, NCT01379742
Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
Phase: Phase IV
Type: Treatment
Status: Active
Age: 21 and over
Sponsor: Other
Protocol IDs: R12-3104L, NCT01581749
Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 30 and over
Sponsor: Other
Protocol IDs: 05-043, NCT00116142
Low Dose Supplemental External Radiation With Pd-103 Versus Pd-103 Alone for Prostate Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 40 to 80
Sponsor: Other
Protocol IDs: 04-8-10, NCT00241384
Pd-103 Dose De-Escalation for Early Stage Prostate Cancer: A Prospective Randomized Trial
Phase: Phase III
Type: Treatment
Status: Active
Age: No age specified
Sponsor: Other
Protocol IDs: 05-8-3, NCT00247312
Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CALGB 90203, U10CA031946, CDR0000526353, NCT00430183
I-125 Versus Pd-103 for Medium Risk Prostate Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 40 to 90
Sponsor: Other
Protocol IDs: 02-4407-V04, NCT00486499
Cholecalciferol Supplement in Treating Patients With Localized Prostate Cancer Undergoing Observation
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: I 128308, NCI-2009-01530, P30CA016056, RPCI-I-128308, NCT00887432
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: RTOG 0815, CDR0000648194, NCI-2011-01948, NCT00936390
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: RTOG-0924, CDR0000701128, NCI-2011-02674, NCT01368588
A Phase III Trial of Hypofractionated External Beam Image-Guided Highly Targeted Radiotherapy: The HEIGHT Trial
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: 35 to 85
Sponsor: Other
Protocol IDs: 20100635, NCT01411332
A Phase III Randomized Trial of MRI-Mapped Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: 35 to 85
Sponsor: Other
Protocol IDs: 20101056, NCT01411345
Trial of Modifications to Radical Prostatectomy
Phase: Phase III
Type: Treatment
Status: Active
Age: 21 and over
Sponsor: Other
Protocol IDs: 11-096, NCT01407263
Phase 3 Study of ProstAtak™ Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PrTK03, NCT01436968
Hypo-fractionated Proton Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: GU003-10, NCT01492972
Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 11-497, NCT01617161
Radiation Hypofractionation Via Extended Versus Accelerated Therapy (HEAT) For Prostate Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 35 to 85
Sponsor: Other
Protocol IDs: 20110491, NCT01794403
A Study of ARN-509 in Men With Non-Metastatic Castration-Resistant Prostate Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR102931, ARN-509-003, 2012-004322-24, NCT01946204
Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MDV3100-14, NCT02003924
Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer (ARAMIS)
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 17712, 2013-003820-36, NCT02200614
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MDV3100-13, NCT02319837
Impact of Robot-assisted Radical Prostatectomy Technique on Short-term Continence Recovery
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 40 to 95
Sponsor: Other
Protocol IDs: 9220, NCT02352103
Study of Hypofractionated Proton Beam Radiation Therapy for Prostate Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 58116, NCT00831623
Radiation and Androgen Ablation for Prostate Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: J11157, NA_00067963, NCT01517451
Start Over